EP
XENE icon

Eversept Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Eversept Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.53M Sell
129,574
-101,806
-44% -$4.69M 0.4% 51
2025
Q4 		$10.4M Buy
+231,380
New +$9.72M 0.52% 50
2025
Q1 		– Sell
-155,540
Closed -$6.1M – 73
2024
Q4 		$6.1M Buy
+155,540
New +$6.43M 0.54% 37
2023
Q3 		– Sell
-171,378
Closed -$6.6M – 78
2023
Q2 		$6.6M Sell
171,378
-31,894
-16% -$1.27M 0.55% 36
2023
Q1 		$7.28M Sell
203,272
-72,432
-26% -$2.68M 0.51% 35
2022
Q4 		$10.9M Buy
275,704
+16,092
+6% +$586K 0.95% 23
2022
Q3 		$9.37M Sell
259,612
-206,299
-44% -$7.42M 0.81% 28
2022
Q2 		$14.2M Buy
465,911
+55,890
+14% +$1.69M 1.01% 31
2022
Q1 		$12.5M Buy
410,021
+200,502
+96% +$6M 0.96% 31
2021
Q4 		$6.55M Buy
+209,519
New +$6.26M 0.42% 58
2020
Q2 		– Sell
-71,591
Closed -$812K – 79
2020
Q1 		$812K Sell
71,591
-144,018
-67% -$2.05M 0.2% 47
2019
Q4 		$2.83M Hold
215,609
– – 0.5% 38
2019
Q3 		$1.94M Sell
215,609
-8,731
-4% -$82.6K 0.6% 36
2019
Q2 		$2.21M Hold
224,340
– – 0.62% 34
2019
Q1 		$2.28M Buy
224,340
+19,236
+9% +$163K 0.66% 29
2018
Q4 		$1.29M Sell
205,104
-4,635
-2% -$41.2K 0.7% 30
2018
Q3 		$2.77M Buy
+209,739
New +$2.43M 1.22% 18

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Eversept Partners's XENE Position: Q1 2026 in Review

Eversept Partners reduced its Xenon Pharmaceuticals (XENE) stake by 44% in Q1 2026, selling an estimated $4.69M and leaving 129,574 shares worth $7.53M. The position accounts for 0.4% of the portfolio, ranked #51.

Eversept Partners first reported a position in XENE in Q3 2018 and has held it in 17 quarters since. The position peaked at $14.2M in Q2 2022. 290 funds tracked by Wall St. Rank hold XENE as of Q1 2026.

  • Eversept Partners held 129,574 shares of Xenon Pharmaceuticals worth $7.53M as of Q1 2026.
  • Eversept Partners sold 101,806 Xenon Pharmaceuticals shares in Q1 2026, an estimated $4.69M.
  • Xenon Pharmaceuticals made up 0.4% of Eversept Partners's portfolio in Q1 2026, its #51 holding.
  • Eversept Partners first reported a position in Xenon Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • Eversept Partners's Xenon Pharmaceuticals position peaked at $14.2M in Q2 2022.
  • 290 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2026.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.